Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia

Sarah Elitzur; Nira Arad-Cohen; Shlomit Barzilai-Birenboim; Miriam Ben-Harush; Bella Bielorai; Ronit Elhasid; Tamar Feuerstein; Gil Gilad; Alexander Gural; Mira Kharit; Naomi Litichever; Ronit Nirel; Sigal Weinreb; Ofir Wolach; Amos Toren; Shai Izraeli; Elad Jacoby

doi:10.1002/pbc.27898

Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia

Sarah Elitzur^*, Nira Arad-Cohen, Shlomit Barzilai-Birenboim, Miriam Ben-Harush, Bella Bielorai, Ronit Elhasid, Tamar Feuerstein, Gil Gilad, Alexander Gural, Mira Kharit, Naomi Litichever, Ronit Nirel, Sigal Weinreb, Ofir Wolach, Amos Toren, Shai Izraeli, Elad Jacoby

^*Corresponding author for this work

Department of Statistics

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.

Original language	American English
Article number	e27898
Journal	Pediatric Blood and Cancer
Volume	66
Issue number	10
DOIs	https://doi.org/10.1002/pbc.27898
State	Published - 2019

Bibliographical note

Funding Information:
This work was supported by the Israel Cancer Association and Amutat Chaim.

Funding Information:
This work was supported by the Israeli Society of Pediatric Hematology-Oncology, the Israel Cancer Association, and Amu-tat Chaim. We thank Dina Kugel for the data collection. We wish to acknowledge all pediatric hematology-oncology departments in Israel for their devoted care of these patients.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Keywords

blinatumomab
childhood acute lymphoblastic leukemia
immunotherapy
treatment-related toxicity

Access to Document

10.1002/pbc.27898

Cite this

Elitzur, S., Arad-Cohen, N., Barzilai-Birenboim, S., Ben-Harush, M., Bielorai, B., Elhasid, R., Feuerstein, T., Gilad, G., Gural, A., Kharit, M., Litichever, N., Nirel, R., Weinreb, S., Wolach, O., Toren, A., Izraeli, S., & Jacoby, E. (2019). Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. Pediatric Blood and Cancer, 66(10), Article e27898. https://doi.org/10.1002/pbc.27898

@article{5ea0ca21035c40b39371d6632545fec9,

title = "Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia",

abstract = "Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.",

keywords = "blinatumomab, childhood acute lymphoblastic leukemia, immunotherapy, treatment-related toxicity",

author = "Sarah Elitzur and Nira Arad-Cohen and Shlomit Barzilai-Birenboim and Miriam Ben-Harush and Bella Bielorai and Ronit Elhasid and Tamar Feuerstein and Gil Gilad and Alexander Gural and Mira Kharit and Naomi Litichever and Ronit Nirel and Sigal Weinreb and Ofir Wolach and Amos Toren and Shai Izraeli and Elad Jacoby",

note = "Funding Information: This work was supported by the Israel Cancer Association and Amutat Chaim. Funding Information: This work was supported by the Israeli Society of Pediatric Hematology-Oncology, the Israel Cancer Association, and Amu-tat Chaim. We thank Dina Kugel for the data collection. We wish to acknowledge all pediatric hematology-oncology departments in Israel for their devoted care of these patients. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

doi = "10.1002/pbc.27898",

language = "American English",

volume = "66",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Elitzur, S, Arad-Cohen, N, Barzilai-Birenboim, S, Ben-Harush, M, Bielorai, B, Elhasid, R, Feuerstein, T, Gilad, G, Gural, A, Kharit, M, Litichever, N, Nirel, R, Weinreb, S, Wolach, O, Toren, A, Izraeli, S & Jacoby, E 2019, 'Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia', Pediatric Blood and Cancer, vol. 66, no. 10, e27898. https://doi.org/10.1002/pbc.27898

Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. / Elitzur, Sarah; Arad-Cohen, Nira; Barzilai-Birenboim, Shlomit et al.
In: Pediatric Blood and Cancer, Vol. 66, No. 10, e27898, 2019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia

T2 - Report from the Israeli Study Group of Childhood Leukemia

AU - Elitzur, Sarah

AU - Arad-Cohen, Nira

AU - Barzilai-Birenboim, Shlomit

AU - Ben-Harush, Miriam

AU - Bielorai, Bella

AU - Elhasid, Ronit

AU - Feuerstein, Tamar

AU - Gilad, Gil

AU - Gural, Alexander

AU - Kharit, Mira

AU - Litichever, Naomi

AU - Nirel, Ronit

AU - Weinreb, Sigal

AU - Wolach, Ofir

AU - Toren, Amos

AU - Izraeli, Shai

AU - Jacoby, Elad

N1 - Funding Information: This work was supported by the Israel Cancer Association and Amutat Chaim. Funding Information: This work was supported by the Israeli Society of Pediatric Hematology-Oncology, the Israel Cancer Association, and Amu-tat Chaim. We thank Dina Kugel for the data collection. We wish to acknowledge all pediatric hematology-oncology departments in Israel for their devoted care of these patients. Publisher Copyright: © 2019 Wiley Periodicals, Inc.

PY - 2019

Y1 - 2019

N2 - Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.

AB - Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.

KW - blinatumomab

KW - childhood acute lymphoblastic leukemia

KW - immunotherapy

KW - treatment-related toxicity

UR - http://www.scopus.com/inward/record.url?scp=85068523452&partnerID=8YFLogxK

U2 - 10.1002/pbc.27898

DO - 10.1002/pbc.27898

M3 - Article

C2 - 31264788

AN - SCOPUS:85068523452

SN - 1545-5009

VL - 66

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 10

M1 - e27898

ER -

Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this